StockData
Stryker Corp logo

Stryker Corp (SYK) KPIs and segments

SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 18/306% below fair value
$318.15+0.61 (+0.19%)

Close on Nov 18, 2026Market cap $121.12BP/E 33.9Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Stryker · năm tài chính kết thúc December 31 (Calendar fiscal year; FY2025 ended December 31, 2025; latest quarter FY2026Q3 ended September 30, 2026)

Nhìn nhanh KPI của Stryker: 44 chỉ số vận hành, trong đó có Consolidated Organic Net Sales Growth YoY, MedSurg & Neurotechnology và Orthopaedics — Organic Net Sales Growth YoY, lấy từ 211 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
MedSurg and Neurotechnology:($M)7
3,6643,6253,2075,9313,3553,3053,0563,8823,3243,2153,0973,754
United States($M)
2,4943,5772,9832,9782,4173,0442,5852,4952,3942,896
Medical($M)
1,0811,1229021,2849859909451,1429389088641,042
Endoscopy($M)
1,0211,0048681,1458968998671,006837768778902
Instruments($M)
9961,003920478949918838790679698667726
International($M)
713985820793639838739720703858
Neuro Cranial($M)
669637616563603541514478764
Neurovascular($M)
566496517539525498406341329327310320
Orthopaedics($M)8
2,8562,9642,8131,2402,7022,7172,8102,5542,1702,2072,1462,061
United States($M)
1,9821,8641,5881,5762,0231,8291,5241,5521,5201,460
Trauma and Extremities($M)
1,0101,0721,0351,086960957945996849832830860
International($M)
831745666675787725646655626601
Ortho Tech($M)
754717646651649617
Knees($M)
635693670749628640639687570602588630
Hips($M)
453479460499457466443463420428393414
Other($M)
267203183162222159167164315
Spinal Implants($M)
432865166186172178171318
Neuro Cranial Instruments($M)
670681606637616563
Orthopaedic Instruments($M)
535523489492501484
Other Orthopedics($M)
219194157159148133
Enabling Technologies($M)
282826453429
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)3
United States($M)
4,9504,9594,4765,4414,5714,5544,4404,8734,1094,0473,9144,356
International($M)
1,5701,6301,5441,7301,4861,4681,4261,5631,3851,3751,3291,459
MedSurg and Neurotechnology:($M)
1,0521,0197002,1948748467571,2889669038471,204
Orthopaedics($M)
8911,008846190876900854794643676605698
MedSurg and Neurotechnology:($M)
2,2972,2821,9163,8042,0612,0411,8812,4002,0111,9281,859
Orthopaedics($M)
2,0382,1421,9909951,9331,9502,0351,8821,6091,6311,555
MedSurg and Neurotechnology:($M)
27,64727,28026,90926,91223,11520,804
Orthopaedics($M)
18,64118,19217,86517,87818,50718,313
Consolidated Organic Net Sales Growth YoY (%)(%)5
7.7%9.0%2.4%11.0%9.5%10.2%10.1%10.2%11.5%9.0%10.0%11.4%
Consolidated Unit Volume & Product Mix Growth YoY (%)(%)
7.6%9.0%2.1%9.1%9.7%10.3%7.9%9.3%
Consolidated Constant Currency Net Sales Growth YoY (%)(%)4
7.7%9.0%1.0%10.4%9.6%10.3%12.8%11.2%12.0%9.4%10.2%11.5%
Consolidated U.S. Constant Currency Sales Growth YoY (%)(%)
8.3%8.9%0.8%11.7%11.4%12.5%13.4%11.8%11.7%9.1%11.4%12.8%
Consolidated International Constant Currency Sales Growth YoY (%)(%)
6.0%9.2%1.5%6.3%4.3%3.9%10.8%9.2%13.0%10.5%6.8%7.8%
Consolidated U.S. Reported Sales Growth YoY (%)(%)
8.3%8.9%0.8%11.7%11.4%12.5%13.4%11.8%11.7%9.1%11.4%12.8%
Consolidated International Reported Sales Growth YoY (%)(%)
5.7%11.0%8.3%10.6%6.9%6.8%7.3%7.2%12.5%7.0%4.9%8.9%
Consolidated Acquisitions & Divestitures Net Impact YoY (%)(%)
0.0%0.0%-1.4%-0.6%0.1%0.1%2.7%1.0%0.5%0.4%0.2%0.1%
Consolidated Foreign Currency Exchange Impact YoY (%)(%)
0.0%0.4%1.6%1.0%0.7%0.8%-0.9%-0.5%-0.1%-0.9%-0.5%0.3%
Consolidated Reported Net Sales Growth YoY (%)(%)
7.7%9.4%2.6%11.4%10.3%11.1%11.9%10.7%11.9%8.5%9.7%11.8%
MedSurg & Neurotechnology — Organic Net Sales Growth YoY (%)(%)6
9.1%9.2%0.9%12.6%8.4%11.0%10.7%10.1%12.7%9.7%11.6%11.8%
MedSurg & Neurotechnology — Unit Volume & Product Mix Growth YoY (%)(%)
8.9%9.1%0.3%7.6%10.2%9.5%11.0%7.6%10.2%
MedSurg & Neurotechnology — Selling Price Growth Impact YoY (%)(%)
0.2%0.1%0.6%0.8%0.8%1.2%1.7%2.1%1.4%
MedSurg & Neurotechnology — Constant Currency Growth YoY (%)(%)
9.2%9.2%3.6%16.6%13.9%16.7%14.2%11.1%12.9%9.8%12.0%12.0%
MedSurg & Neurotechnology — Acquisitions / Divestitures Impact YoY (%)(%)
0.1%0.0%2.7%4.0%5.5%5.7%3.5%1.0%0.2%0.1%0.4%0.2%
MedSurg & Neurotechnology — Foreign Currency Impact YoY (%)(%)
0.0%0.5%1.4%0.9%0.5%0.6%-0.8%-0.5%-0.1%-0.8%-0.5%0.3%
MedSurg & Neurotechnology — Reported Growth YoY (%)(%)
9.2%9.7%5.0%17.5%14.4%17.3%13.4%10.6%12.8%9.0%11.5%12.3%
Orthopaedics — Organic Net Sales Growth YoY (%)(%)5
5.9%8.6%4.1%8.4%11.4%9.0%9.3%10.2%9.7%8.0%8.0%10.7%
Orthopaedics — Unit Volume & Product Mix Growth YoY (%)(%)
5.9%8.6%4.1%11.7%9.0%9.3%9.3%8.4%8.2%
Orthopaedics — Constant Currency Growth YoY (%)(%)
5.9%8.7%-1.8%0.9%3.1%1.1%10.7%11.3%10.8%8.9%8.0%10.7%
Orthopaedics — Acquisitions / Divestitures Impact YoY (%)(%)
0.0%0.1%-5.9%-7.5%-8.3%-7.9%1.4%1.1%1.1%0.9%0.0%0.0%
Orthopaedics — Foreign Currency Impact YoY (%)(%)
-0.2%0.4%1.9%1.3%0.8%0.9%-1.0%-0.5%-0.1%-1.0%-0.5%0.3%
Orthopaedics — Reported Growth YoY (%)(%)
5.7%9.1%0.1%2.2%3.9%2.0%9.7%10.8%10.7%7.9%7.5%11.0%
Adjusted Non-GAAP Operating Margin (%)(%)13
26.2%27.4%21.1%30.2%25.6%25.7%22.9%29.2%24.7%24.6%21.9%27.2%
Adjusted Non-GAAP Gross Margin (%)(%)
65.4%66.0%63.6%65.2%65.0%65.4%65.5%65.3%64.5%64.2%63.6%63.9%
Adjusted Non-GAAP Net Margin (%)(%)
20.8%21.6%16.7%24.1%20.4%20.1%18.7%24.0%20.1%20.0%18.3%22.8%
Adjusted R&D Expense (% of Net Sales)(%)
6.4%6.4%6.7%5.3%6.6%6.6%6.7%5.3%6.6%6.5%6.8%5.6%
Adjusted SG&A Expense (% of Net Sales)(%)
32.8%32.2%35.8%29.7%32.8%33.1%35.9%30.8%33.2%33.1%35.0%31.0%
Adjusted Effective Income Tax Rate (%)(%)
16.0%16.5%14.5%16.1%14.0%15.9%13.7%15.4%15.8%15.2%12.3%14.6%
MedSurg & Neurotechnology Segment Operating Margin (%)(%)
28.7%28.1%21.8%29.0%28.3%27.6%28.7%27.6%26.8%
Orthopaedics Segment Operating Margin (%)(%)
31.2%34.0%30.1%28.8%30.1%27.2%28.3%29.3%27.0%
Consolidated Gross Margin Bridge — Volume & Product Mix Impact (bps)(bps)
607010707080605060
Consolidated Gross Margin Bridge — Manufacturing, Cost & Tariffs Impact (bps)(bps)
-20-30-200-304070-90-80-40
MedSurg Segment Margin Bridge — Volume & Mix Impact (bps)(bps)
7060209010080340250370
MedSurg Segment Margin Bridge — Manufacturing & Cost Impact (bps)(bps)
5060-220110130120-310-90190
Orthopaedics Segment Margin Bridge — Volume & Mix Impact (bps)(bps)
4050-10201080530740160
Orthopaedics Segment Margin Bridge — Manufacturing & Cost Impact (bps)(bps)
-70-20-190-190-5040180-320-50
Adjusted Non-GAAP Diluted Net Earnings per Share ($)($)8
3.523.692.604.473.193.132.844.012.872.812.503.46
Full-Year Guidance Issued in Quarter — Organic Net Sales Growth Low End (%)(%)3
6.5%8.3%8.0%8.0%8.0%9.5%9.0%8.5%7.5%
Full-Year Guidance — Organic Net Sales Growth High End (%)(%)
7.0%9.3%9.5%9.5%9.0%10.0%10.0%9.5%9.0%
Full-Year Guidance — Adjusted Diluted EPS Low End ($)($)
14.8014.9514.9014.9013.5013.4013.451211.9011.8511.70
Full-Year Guidance — Adjusted Diluted EPS High End ($)($)
14.9015.1015.1015.1013.6013.6013.7012.1012.1012.0512
MedSurg & Neurotechnology Segment — Worldwide Net Sales ($M)($M)4
3,6643,6253,2073,9763,3553,3053,0564,1783,3243,2153,0973,427
MedSurg & Neurotechnology — Worldwide Constant Currency Growth YoY (%)(%)
9.2%9.2%3.6%
MedSurg & Neurotechnology — Worldwide Reported Growth YoY (%)(%)
9.2%9.7%5.0%
MedSurg & Neurotechnology — U.S. Net Sales ($M)($M)
2,9042,8542,4943,1222,6502,6262,4172,6802,2672,1562,0722,363
MedSurg & Neurotechnology — International Net Sales ($M)($M)
760771713854705679639720639617602702
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — Worldwide Net Sales ($M)($M)6
9961,0039201,008949918838679698667
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — Worldwide Constant Currency Sales Growth YoY (%)(%)
5.2%9.0%8.7%
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — Worldwide Reported Sales Growth YoY (%)(%)
5.1%9.3%9.9%
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — U.S. Net Sales ($M)($M)1
835840766848797776702769674643600663
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
4.8%8.4%9.1%
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — International Net Sales ($M)($M)2
161163154160152142136142128127122138
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — International Constant Currency Sales Growth YoY (%)(%)
7.1%12.3%7.0%
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — International Reported Sales Growth YoY (%)(%)
6.5%13.9%14.0%
Standalone Sub-Portfolio: Neuro Cranial — Worldwide Net Sales ($M)($M)3
670681606669637616563603441416380437
Neuro Cranial (Legacy Standalone through FY2025Q4) — Worldwide CC Growth YoY (%)(%)
10.2%17.0%19.2%18.5%15.8%15.0%12.2%7.5%13.8%
Neuro Cranial (Legacy Standalone through FY2025Q3) — U.S. Net Sales ($M)($M)
524507465366339309
Neuro Cranial (Legacy Standalone through FY2025Q3) — International Net Sales ($M)($M)
11310998757771
Instruments (Legacy Pre-2026 Basis, through FY2025Q4) — Worldwide Net Sales ($M)($M)3
925760768730790679698667736
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — Worldwide Net Sales ($M)($M)4
1,0211,0048681,1458968998671,006837768778892
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — Worldwide Constant Currency Sales Growth YoY (%)(%)
14.0%11.3%-1.0%13.6%6.7%16.7%12.1%12.3%12.5%8.3%10.5%14.4%
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — Worldwide Reported Sales Growth YoY (%)(%)
13.9%11.7%0.1%13.8%7.0%17.1%11.4%11.5%12.2%7.6%10.1%14.6%
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — U.S. Net Sales ($M)($M)1
839819701938743742710844689623636747
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
13.0%10.2%-1.2%11.1%7.9%19.1%11.6%13.1%11.3%8.2%11.1%17.9%
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — International Net Sales ($M)($M)2
182185167207153157157162148145142155
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — International Constant Currency Sales Growth YoY (%)(%)
18.5%16.5%0.0%26.3%0.8%6.4%14.6%8.2%18.1%9.0%8.1%0.6%
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — International Reported Sales Growth YoY (%)(%)
18.0%18.8%6.0%28.1%2.6%8.3%10.6%3.9%16.6%5.3%5.9%1.1%
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — Worldwide Net Sales ($M)($M)4
1,0811,1229021,2849859909451,1429389088641,042
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — Worldwide Constant Currency Sales Growth YoY (%)(%)
9.8%13.0%-5.6%11.3%4.7%8.6%10.1%10.1%17.7%8.4%11.1%11.2%
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — Worldwide Reported Sales Growth YoY (%)(%)
9.7%13.4%-4.6%12.4%5.1%9.0%9.4%9.6%17.6%8.0%11.0%11.4%
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — U.S. Net Sales ($M)($M)1
9109457471,042827840802930783763715831
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
10.0%12.6%-6.9%12.0%5.6%10.1%12.3%12.0%18.6%11.9%16.8%12.9%
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — International Net Sales ($M)($M)2
171177155242158150143212155145149211
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — International Constant Currency Sales Growth YoY (%)(%)
8.5%15.0%1.1%8.0%0.3%1.2%-0.6%2.9%13.2%-6.5%-9.5%4.9%
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — International Reported Sales Growth YoY (%)(%)
8.1%17.9%8.3%13.7%2.8%3.4%-4.3%0.1%12.7%-8.7%-10.3%6.0%
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — Worldwide Net Sales ($M)($M)4
566496517539525498406341329327310320
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — Worldwide Constant Currency Sales Growth YoY (%)(%)
7.4%-1.8%24.0%55.8%58.9%50.7%33.3%7.8%5.9%8.0%11.4%6.6%
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — Worldwide Reported Sales Growth YoY (%)(%)
8.0%-0.7%27.5%58.1%59.6%52.3%31.0%6.8%5.5%5.3%9.1%6.7%
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — U.S. Net Sales ($M)($M)1
320250280294283268203137121127121122
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
13.0%-6.7%37.9%115.9%136.9%111.0%67.0%12.0%1.5%2.3%2.9%7.6%
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — International Net Sales ($M)($M)2
246246237245242230203204208200189198
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — International Constant Currency Sales Growth YoY (%)(%)
0.8%4.0%10.5%15.8%12.4%11.7%11.1%5.3%8.6%11.8%17.5%6.1%
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — International Reported Sales Growth YoY (%)(%)
2.1%6.3%17.0%19.6%14.3%15.0%7.9%3.6%8.1%7.3%13.4%6.2%
Orthopaedics Segment — Worldwide Net Sales ($M)($M)4
2,8562,9642,8133,1952,7022,7172,8102,2582,1702,2072,1462,388
Orthopaedics — Worldwide Constant Currency Growth YoY (%)(%)
5.9%8.7%-1.8%
Orthopaedics — Worldwide Reported Growth YoY (%)(%)
5.7%9.1%0.1%
Orthopaedics — U.S. Net Sales ($M)($M)
2,0462,1051,9822,3191,9211,9282,0232,1931,8421,8911,8421,993
Orthopaedics — International Net Sales ($M)($M)
810859831876781789787843746758727757
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — Worldwide Net Sales ($M)($M)5
754717646853651649617
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — Worldwide Constant Currency Sales Growth YoY (%)(%)
16.0%10.0%3.2%
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — Worldwide Reported Sales Growth YoY (%)(%)
15.8%10.3%4.8%
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — U.S. Net Sales ($M)($M)1
576530467657487483459520429463434495
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
18.1%9.5%2.0%
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — International Net Sales ($M)($M)2
178187179196164166158184148146153171
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — International Constant Currency Sales Growth YoY (%)(%)
9.5%11.8%6.5%
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — International Reported Sales Growth YoY (%)(%)
9.0%12.8%12.9%
Other Orthopaedics (Legacy Pre-2026 Basis, through FY2025Q4) — Worldwide Net Sales ($M)($M)3
267203183162222127136133166
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — Worldwide Net Sales ($M)($M)4
635693670749628640639687570602588630
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — Worldwide Constant Currency Sales Growth YoY (%)(%)
1.2%8.0%2.8%7.9%9.6%5.6%9.8%9.5%10.7%8.0%4.5%13.9%
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — Worldwide Reported Sales Growth YoY (%)(%)
1.1%8.4%4.7%8.9%10.2%6.3%8.7%9.0%10.6%7.1%4.0%14.2%
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — U.S. Net Sales ($M)($M)1
458488472548452460464509417433429469
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
1.3%6.2%1.4%7.6%8.4%6.2%8.3%8.5%8.4%6.6%3.1%12.9%
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — International Net Sales ($M)($M)2
177205198201176180175178153169159161
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — International Constant Currency Sales Growth YoY (%)(%)
1.1%12.4%6.1%8.8%12.7%4.1%13.9%12.3%17.4%11.7%8.2%16.9%
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — International Reported Sales Growth YoY (%)(%)
0.5%14.0%13.5%12.8%14.9%6.5%10.0%10.7%17.1%8.2%6.3%18.0%
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — Worldwide Net Sales ($M)($M)4
453479460499457466443463420428393414
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — Worldwide Constant Currency Sales Growth YoY (%)(%)
-0.7%2.6%1.2%6.6%7.9%7.5%14.1%12.2%16.2%10.6%6.1%10.3%
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — Worldwide Reported Sales Growth YoY (%)(%)
-1.0%2.9%3.7%8.1%8.9%8.9%12.7%11.6%15.9%8.9%5.1%10.2%
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — U.S. Net Sales ($M)($M)1
277296276306279283269291256261251271
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
-0.6%4.9%2.3%5.6%8.7%8.4%7.6%7.1%10.9%4.3%6.8%12.9%
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — International Net Sales ($M)($M)2
176183184193178183174172164167142143
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — International Constant Currency Sales Growth YoY (%)(%)
-0.8%-0.8%-0.3%8.4%6.8%6.3%25.7%21.6%25.3%21.7%5.0%5.8%
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — International Reported Sales Growth YoY (%)(%)
-1.7%0.0%6.0%12.3%9.2%9.6%21.7%20.2%24.8%16.9%2.1%5.5%
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — Worldwide Net Sales ($M)($M)4
1,0101,0721,0351,086960957945996849832830860
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — Worldwide Constant Currency Sales Growth YoY (%)(%)
5.5%11.5%7.4%7.6%11.9%14.0%14.7%16.1%12.6%9.3%8.0%10.3%
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — Worldwide Reported Sales Growth YoY (%)(%)
5.3%11.9%9.5%9.1%13.0%15.0%13.9%15.8%12.8%8.6%7.9%11.0%
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — U.S. Net Sales ($M)($M)1
735791767808703702713744621610611633
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
4.5%12.5%7.6%8.5%13.2%15.1%16.6%17.4%12.9%9.1%10.3%12.1%
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — International Net Sales ($M)($M)2
275281268278257255232252228222219227
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — International Constant Currency Sales Growth YoY (%)(%)
8.4%8.5%6.8%4.9%8.5%10.5%9.2%12.5%12.0%9.8%2.1%5.5%
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — International Reported Sales Growth YoY (%)(%)
7.5%10.3%15.3%10.8%12.5%14.9%6.0%11.5%12.6%7.4%1.7%8.3%
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — Worldwide Net Sales ($M)($M)4
432865166186304307300318
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — Worldwide Constant Currency Sales Growth YoY (%)(%)
-45.4%-40.9%-99.0%-96.1%-96.9%-97.0%-2.4%3.7%4.4%4.4%5.7%6.5%
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — Worldwide Reported Sales Growth YoY (%)(%)
-43.9%-36.7%-98.9%-95.8%-96.7%-97.2%-2.9%3.2%4.6%3.8%5.5%7.0%
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — U.S. Net Sales ($M)($M)1
000000118129119124117125
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%)
0.0%-100.0%-100.0%-100.0%-100.0%-100.0%-0.1%2.3%3.5%4.4%3.9%6.0%
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — International Net Sales ($M)($M)2
432865485753545455
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — International Constant Currency Sales Growth YoY (%)(%)
-45.4%-40.9%-96.6%-87.5%-89.7%-90.2%-7.6%6.9%6.8%4.3%11.1%7.7%
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — International Reported Sales Growth YoY (%)(%)
-43.9%-36.7%-96.2%-86.5%-89.3%-90.7%-10.5%5.2%7.5%2.0%10.2%9.9%
Customer Contract Liabilities (Deferred Service, Protection Plans & Placed Equipment, $M)($M)2
9609971,0351,0249391,0611,0289781,008921866860
Accounts Receivable Allowance for Credit Losses ($M)($M)
226215225216223222221213200186175182
Accrued Employee Compensation & Benefits Liability ($M)($M)
1,3631,1058851,5951,3061,0759191,4031,2508877781,478
Inventories by Production Stage — Total ($M)($M)4
5,7475,5215,4195,3105,3705,2895,1054,7745,2925,0445,0264,843
Finished Goods Inventory ($M)($M)
3,8863,6153,5113,5463,5573,5483,5113,2913,6673,5013,4223,271
Work-in-Process (WIP) Inventory ($M)($M)
484470435415442436398336391380372330
Raw Materials & Supplies Inventory ($M)($M)
1,3771,4361,4731,3491,3711,3051,1961,1471,2341,1631,2321,242
Acquisition Inventory Fair-Value Step-Up Amortization ($M)($M)
000136165342990
Other Intangible Assets, Net ($M)($M)6
5,5425,7425,5165,6815,8455,9626,1324,3954,9404,3634,5094,593
Global Manufacturing Sites (sites)1
Operating Lease Cost ($M)($M)
525356524852534647504745
Acquisition & Integration-Related Costs (GAAP Footnote, $M)($M)3
172519333978185214814-1313
Share Repurchases — Shares Repurchased (Monthly & Quarterly, millions)(M)1
300000000000
Share Repurchase Authorization Remaining (millions of shares)(M)
331,0331,0331,0331,0331,0331,0331,0331,0331,0331,0331,033
Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Total Revenue ($M)($M)4
153146143132
Inari Medical (Standalone through FY2024Q3) — Venous Thromboembolism (VTE: ClotTriever & FlowTriever) Revenue ($M)($M)
145138137
Inari Medical (Standalone through FY2024Q3) — Emerging Therapies Revenue ($M)($M)
8.048.156
Inari Medical (Standalone through FY2024Q3) — U.S. Revenue ($M)($M)
142136134124
Inari Medical (Standalone through FY2024Q3) — International Revenue ($M)($M)
11.510.09.517.70
Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Gross Margin (%)(%)8
87.1%86.3%86.8%87.1%
Inari Medical (Standalone through FY2024Q3) — Gross Profit ($M)($M)
134126124115
Inari Medical (Standalone through FY2024Q3) — Cost of Goods Sold ($M)($M)
19.920.018.917.0
Inari Medical (Standalone through FY2024Q3) — Research & Development Expense ($M)($M)
29.424.926.922.9
Inari Medical (Standalone through FY2024Q3) — Selling, General & Administrative Expense ($M)($M)
108114103101
Inari Medical (Standalone through FY2024Q3) — Operating Income / (Loss) ($M)($M)
-13.6-22.4-17.2-9.30
Inari Medical (Standalone through FY2024Q3) — Net Income / (Loss) ($M)($M)
-18.4-31.4-24.2-4.67
Inari Medical (Standalone through FY2024Q3) — Operating Cash Flow ($M)($M)
2.7111.5-12.312.2
Inari Medical (Standalone through FY2024Q3) — Capital Expenditures ($M)($M)
2.893.761.250.91
Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Inventories Total ($M)($M)7
55.249.444.742.9
Inari Medical — U.S. FDA 510(k) Clearances (Ongoing Post-Acquisition, clearances)1
200201111022
Inari Medical — FDA MAUDE Adverse Event Reports (reports)
232429362218232014151715
Stryker — U.S. FDA 510(k) Device Clearances (clearances)6
81110710581296115
U.S. MedTech Industry Total — FDA 510(k) Clearances (clearances)
855923756806797886736856767793713877
Stryker — U.S. FDA Premarket Approvals (PMA & Supplements, approvals)
211123147312
U.S. MedTech Industry Total — FDA PMA Approvals (approvals)
565608567525585588524683538550459656
Stryker — openFDA Device Recall Events (events)
183036452581722234
Stryker — openFDA Enforcement Reports (reports)
193027323791721235
Stryker — FDA MAUDE Adverse Event Reports Total (reports)4
2,7551,8562,0372,6682,5052,6932,5012,7962,8582,4112,3902,477
Stryker — Clinical Trials Started in Period (ClinicalTrials.gov, studies)
4321114534
Consolidated Net Sales ($M)($M)15
6,5206,5896,0207,1716,0576,0225,8666,4365,4945,4225,2435,815
Total Assets ($M)($M)11
47,24747,93046,29147,84447,05746,33146,00642,97143,83339,13039,40239,912
Operating Cash Flow ($M)($M)6
1,4611,2615812,1431,5401,1112501,9311,4746332041,528

25 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Operational & Franchise KPIs (Groups 1–3): Consolidated and segment Organic Sales Growth (%), MD&A Constant-Currency Unit Volume/Mix (%) vs. Selling Price (%) growth decomposition, Gross & Segment Margin Bridge drivers (bps), Full-Year Organic Sales & Adjusted EPS Guidance ranges, and all 9 active Q1-2026 franchises across Worldwide, U.S., and International markets plus standalone Other Orthopaedics (Mako SmartRobotics Capital), Orthopaedic Instruments, Neuro Cranial, and Enabling Technologies sub-portfolios.
  • Q1 2026 Ortho Tech & Instruments Reclassification (Step 5): Effective Q1 2026, Stryker formed Ortho Tech by moving Orthopaedic Instruments and Enabling Technologies out of Instruments into Orthopaedics, and folded Neuro Cranial into Instruments. Official recast schedules (FY2023Q1–FY2026Q3) are merged seamlessly; pre-2026 historical series are preserved as labeled Legacy child rows through FY2025Q4.
  • Consolidated − Standalone Evaluation (Step 3 & Step 4): Stryker Corporation files consolidated US GAAP financial statements on Form 10-K/10-Q without parent-only Schedule I financial statements, so consolidated − standalone subtraction does not apply. Instead, acquired peripheral vascular leader Inari Medical, Inc. (Nasdaq: NARI, CIK 0001531048 — acquired Feb 2025 for $4,810M) and Stryker UK Limited (Co. 03669454) are tracked directly from their self-reported filings in Groups 5–6.
  • Period Splitting (Step 4): Only cumulative-to-period subtraction (FY − 9M and YTD − prior YTD on identical reporting versions) is used for Q4 2025 recast sub-portfolios, XBRL/DB Q4 segment values, and Q2–Q4 cash flow statements. Zero self-calculated ratios, margins, shares, sums, or YoY rates exist anywhere in output/kpis.json.

Không hiện vì thiếu các kỳ gần đây (12)

  • Mako SmartRobotics Global Installed Base ('more than 3,000 systems worldwide') & Cumulative Procedures ('more than 2,000,000' / '2.5M+') — Disclosed as lower bounds ('more than 3,000', 'over two-thirds of knees', 'over one-third of hips', '200+ Mako systems contracted for ASCs', '460+ ASC partnerships'); excluded as bounded figures.
  • Annual Patients Impacted Worldwide ('more than 150 million patients annually') — Disclosed as lower bounds ('more than 150 million' in 2024–2025, 'more than 130 million' in 2022); excluded as bounded figures.
  • Earnings Call Transcript Franchise & U.S./International Organic Sales Growth % (Q2 2025, Q4 2025, Q2 2026, Q3 2026) — During the Q1 2026 earnings call (late-quarter cybersecurity incident), management did not provide organic growth figures by division/region, leaving the series missing FY2026Q1 (< 3 consecutive quarters); the table uses the complete 15–45 consecutive quarter Constant Currency Growth YoY (%) series from Form 8-K.
  • Quarterly Consolidated & Orthopaedics Selling Price Impact YoY % (Form 10-Q MD&A) — In Q2 2026, consolidated pricing was flat ('Pricing was flat'), and Form 10-Q omitted the price change clause, leaving the quarterly series missing FY2026Q2; retained a continuous 7-year annual series (FY2019–FY2025) and the full quarterly series for MedSurg & Neurotechnology.
  • Monthly Share Repurchase Average Price Paid per Share ($) — In months with no share repurchases (Q1–Q2 2026 and 07/2026 = 0 shares), the average purchase price is undefined, leaving only the 2 most recent months (2026-08, 2026-09 < 3 consecutive months).
  • Purchased Energy Use by Fuel Type (Non-Renewable, Renewable, Natural Gas, Total TJ — FY2019–FY2022) — The 2024–2025 Comprehensive Report discontinued disclosure of the detailed TJ table by fuel, missing FY2024–FY2025.
  • Manufacturing Total Recordable Incident Rate (TRIR: 0.95 in FY2022 vs. 0.68 in FY2025) — Only reports 2 endpoints (FY2022 and FY2025), missing FY2024 and therefore lacking the 2 most recent consecutive years.
  • External Industry, FDA Regulatory, Clinical Trials & U.S. Federal Contracts › U.S. Hospitals Quarterly Revenue (Census QSS REV622TAXABL144QNSA, $M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
  • Database Context — Operating Segments & Geographic Disaggregation › MedSurg and Neurotechnology — Segment Revenue ($M) › MedSurg and Neurotechnology — Segment Depreciation & Amortization ($M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
  • Database Context — Operating Segments & Geographic Disaggregation › MedSurg and Neurotechnology — Segment Revenue ($M) › MedSurg and Neurotechnology — Segment Total Assets ($M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
  • Database Context — Operating Segments & Geographic Disaggregation › Orthopaedics — Segment Revenue ($M) › Orthopaedics — Segment Depreciation & Amortization ($M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
  • Database Context — Operating Segments & Geographic Disaggregation › Orthopaedics — Segment Revenue ($M) › Orthopaedics — Segment Total Assets ($M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025

Dữ liệu cập nhật 2026-11-02.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Database Context — Consolidated Income Statement (US GAAP)

Database Context — Consolidated Balance Sheet (US GAAP)

Database Context — Consolidated Cash Flow Statement (US GAAP)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Stryker

See a number that looks wrong?